Your Cart is Empty
Aging is the single greatest risk factor for many chronic diseases, including heart disease, diabetes, neurodegenerative disorders, and frailty. As scientists study why the body becomes more vulnerable with age, one molecule has attracted growing attention: NAD⁺ (nicotinamide adenine dinucleotide).
NAD⁺ is found in every living cell and plays a central role in energy production, cellular repair, stress resistance, and metabolic regulation. It helps cells convert food into usable energy and supports proteins involved in DNA repair and healthy cellular function(1,2).
Over time, NAD⁺ levels appear to decline in at least some tissues.
Researchers believe this decline may contribute to several features of biological aging, including:
Mitochondria are often described as the cell’s “power plants” because they generate most of the energy cells need to function. When mitochondrial performance declines, tissues such as muscle, brain, and heart may become less resilient over time.
This growing understanding of NAD⁺ biology has fueled interest in therapies and supplements designed to raise NAD⁺ levels.
Several compounds can serve as building blocks the body uses to produce NAD⁺.
Nicotinamide riboside and Nicotinamide mononucleotide have become especially popular in the longevity and wellness market.
Importantly, these compounds are not NAD⁺ itself. They are precursor molecules that the body must convert into NAD⁺ through a series of metabolic steps(3).
A useful way to think about this is that Nicotinamide riboside and Nicotinamide mononucleotide function more like raw materials than finished fuel. The body still must process and assemble them before they can contribute to cellular NAD⁺ stores.
In rodents, NAD⁺-boosting strategies have often produced striking results.
Healthspan refers to the portion of life spent in relatively good physical and cognitive health, rather than simply the total number of years lived.
In some experiments, older animals given NAD⁺-related compounds appeared biologically younger or more resilient than untreated animals(4,5). These findings helped drive enthusiasm for NAD⁺ supplementation and accelerated interest in human studies.
At the same time, animal research has important limitations.
Animal studies are valuable for understanding biological mechanisms and generating hypotheses, but they do not guarantee similar results in people.
Human aging is extraordinarily complex. Genetics, medications, chronic diseases, sleep, diet, stress, environmental exposures, and decades of accumulated wear all influence how the body ages and responds to interventions.
A treatment that improves metabolism or physical performance in genetically similar laboratory mice living in tightly controlled environments may behave very differently in humans with diverse lifestyles and medical histories.
This gap between promising animal data and mixed human outcomes is common throughout medical research, particularly in aging science.
In human trials, oral Nicotinamide riboside and Nicotinamide mononucleotide consistently increased NAD⁺-related molecules in blood or cells. From a biochemical standpoint, the supplements clearly engaged the intended pathway(6,7).
That finding is important, but it does not necessarily mean the supplements produce health benefits.
Some studies did report modest benefits in specific groups or for certain measurements, but the overall picture remained inconsistent(6-8).
This distinction is important because a therapy can alter a laboratory marker without producing measurable improvements in how people feel, function, or age.
An increase in NAD⁺ levels may indicate that the biological system has been activated, but activation alone does not guarantee clinical benefit.
Several factors are likely to contribute to the mixed findings. Aging involves many interconnected systems, and not driven by a single pathway.
Boosting NAD⁺ may influence some of these systems, but it is unlikely to fully address the broader biology of aging on its own.
Many clinical trials lasted only weeks or months. Aging, however, unfolds over decades. A short study may be able to detect biochemical changes in the bloodstream but still be too brief to determine whether an intervention alters long-term health, physical function, or disease risk.
Several studies included relatively few participants, which limits the ability to detect subtle clinical effects. Small studies are also more vulnerable to inconsistent findings and chance-positive results.
Most human studies measured NAD⁺-related compounds in blood samples. But scientists are especially interested in whether NAD⁺ levels increase inside critical tissues such as muscle, liver, heart, and brain.
That distinction is important because blood markers do not always mirror what is happening deeper inside the body.
Some studies found increases in circulating NAD⁺ markers without clear evidence of changes in skeletal muscle tissue, suggesting that tissue-level responses may be more limited or variable than blood tests alone imply(8).
These treatments are often marketed as ways to rapidly restore cellular energy, improve mental clarity, or reverse aspects of aging.
At present, however, there is very little high-quality clinical evidence showing that IV NAD⁺ therapy produces anti-aging or wellness benefits in humans. The underlying biology also raises important questions about how these treatments actually work(9).
Some marketing claims imply that IV NAD⁺ enters cells directly and immediately replenishes intracellular NAD⁺ stores. Current evidence suggests the process is probably far more indirect.
NAD⁺ is a relatively large, charged molecule that does not easily cross cell membranes. Instead, researchers believe much of it is likely broken down outside cells into smaller components before those components are absorbed and rebuilt into NAD⁺ internally(9,10).
In practical terms, the body may treat IV NAD⁺ less like a finished product delivered directly into the cell and more like raw material that must first be dismantled, processed, and reassembled.
This does not prove IV NAD⁺ is ineffective. It does mean that many simplified marketing claims are not strongly supported by current mechanistic evidence.
So far, short-term studies suggest that NR and NMN are generally well tolerated in most participants. Serious side effects have not been consistently observed in controlled trials over the study periods examined(6,7).
This is an important distinction in longevity science. A supplement may appear safe over several months while its long-term effects remain uncertain.
At this stage, NAD⁺ boosters are best viewed as scientifically interesting but still experimental interventions. The evidence strongly supports the idea that NR and NMN can influence NAD⁺ biology in humans. What remains unclear is whether those biochemical changes reliably translate into improvements in aging, physical function, disease prevention, or lifespan.
That uncertainty is not unusual in medicine. Biological plausibility is an important first step, but therapies ultimately need to demonstrate measurable real-world benefit in rigorous human trials.
One of the clearest messages from the research is that NAD⁺ supplements should not be viewed as substitutes for proven lifestyle interventions.
These interventions consistently produce broader and more reliable benefits than any currently available anti-aging supplement.
If NAD⁺-related therapies ultimately prove useful, they will most likely function as additions to these foundational habits rather than replacements for them.
Current evidence supports several conclusions.
At present, NAD⁺ boosters remain an active and promising area of research, but the evidence does not yet support many of the stronger claims commonly made in the anti-aging marketplace.
The science is evolving and the enthusiasm is understandable, but the clinical evidence is still catching up to the marketing.
References:
